Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.
Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, Held G, Brossart P, Lübbert M, Salih HR, Kindler T, Horst HA, Wulf G, Nachbaur D, Götze K, Lamparter A, Paschka P, Gaidzik VI, Teleanu V, Späth D, Benner A, Krauter J, Ganser A, Döhner H, Döhner K; German-Austrian AML Study Group. Schlenk RF, et al. Among authors: kayser s. Blood. 2014 Nov 27;124(23):3441-9. doi: 10.1182/blood-2014-05-578070. Epub 2014 Sep 30. Blood. 2014. PMID: 25270908 Free article. Clinical Trial.
Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7.
Fröhling S, Lipka DB, Kayser S, Scholl C, Schlenk RF, Döhner H, Gilliland DG, Levine RL, Döhner K. Fröhling S, et al. Among authors: kayser s. Blood. 2006 Feb 1;107(3):1242-3. doi: 10.1182/blood-2005-09-3644. Blood. 2006. PMID: 16434499 Free PMC article. No abstract available.
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.
Fröhling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Döhner K, Döhner H; German-Austrian AML Study Group. Fröhling S, et al. Among authors: kayser s. Blood. 2006 Nov 15;108(10):3280-8. doi: 10.1182/blood-2006-04-014324. Epub 2006 Jul 13. Blood. 2006. PMID: 16840728 Free article. Clinical Trial.
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.
Schlenk RF, Döhner K, Kneba M, Götze K, Hartmann F, Del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, Habdank M, Späth D, Groner S, Krebs B, Kayser S, Corbacioglu A, Anhalt A, Benner A, Fröhling S, Döhner H; German-Austrian AML Study Group (AMLSG). Schlenk RF, et al. Among authors: kayser s. Haematologica. 2009 Jan;94(1):54-60. doi: 10.3324/haematol.13378. Epub 2008 Dec 4. Haematologica. 2009. PMID: 19059939 Free PMC article. Clinical Trial.
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.
Kayser S, Schlenk RF, Londono MC, Breitenbuecher F, Wittke K, Du J, Groner S, Späth D, Krauter J, Ganser A, Döhner H, Fischer T, Döhner K; German-Austrian AML Study Group (AMLSG). Kayser S, et al. Blood. 2009 Sep 17;114(12):2386-92. doi: 10.1182/blood-2009-03-209999. Epub 2009 Jul 14. Blood. 2009. PMID: 19602710 Free article. Clinical Trial.
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
Gröschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C, van Putten WJ, Kayser S, Verdonck LF, Lübbert M, Ossenkoppele GJ, Germing U, Schmidt-Wolf I, Schlegelberger B, Krauter J, Ganser A, Döhner H, Löwenberg B, Döhner K, Delwel R. Gröschel S, et al. Among authors: kayser s. J Clin Oncol. 2010 Apr 20;28(12):2101-7. doi: 10.1200/JCO.2009.26.0646. Epub 2010 Mar 22. J Clin Oncol. 2010. PMID: 20308656
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K. Paschka P, et al. Among authors: kayser s. J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21. J Clin Oncol. 2010. PMID: 20567020
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruiter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B, Döhner H. Lugthart S, et al. Among authors: kayser s. J Clin Oncol. 2010 Aug 20;28(24):3890-8. doi: 10.1200/JCO.2010.29.2771. Epub 2010 Jul 26. J Clin Oncol. 2010. PMID: 20660833
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.
Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kündgen A, Götze K, Rummel M, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Zucknick M, Ganser A, Döhner H, Schlenk RF; German-Austrian AMLSG. Kayser S, et al. Blood. 2011 Feb 17;117(7):2137-45. doi: 10.1182/blood-2010-08-301713. Epub 2010 Dec 2. Blood. 2011. PMID: 21127174 Free article. Clinical Trial.
250 results